Kyverna Therapeutics (“Kyverna”) today announced that it will be hosting a CAR T-cell Symposium to discuss investigational treatment options in Severe Neurological Autoimmune Diseases in Berlin, Germany on November 10, 2023.
| |
| [10-November-2023] |
| Individual patients with severe neurological autoimmune diseases have been treated in Germany with CD19 CAR T-cell therapy EMERYVILLE, Calif., Nov. 10, 2023 /PRNewswire/ -- Kyverna Therapeutics (“Kyverna”), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced that it will be hosting a CAR T-cell Symposium to discuss investigational treatment options in Severe Neurological Autoimmune Diseases in Berlin, Germany on November 10, 2023.
With this symposium, Kyverna wants to support the scientific exchange about investigational chimeric antigen receptor (CAR) T-cell treatment options amongst healthcare professionals active in treating neurological autoimmune disorders. Chairman of the symposium will be Prof. Ralf Gold, Director, Neurology Clinic, St. Josef Hospital in Bochum, Germany. “Through our research and development efforts and by providing a stage for scientific exchange for internationally recognized experts, we are striving to contribute to changing the lives of patients with severe and refractory neuro-immunological diseases like myasthenia gravis,” said Peter Maag, Ph.D., chief executive officer of Kyverna Therapeutics. “We appreciate patients and care team in cell therapy centers around the world that engage with us to evaluate the potentially paradigm shifting treatment option offered by CAR T-cell therapies.”
About Kyverna Therapeutics Kyverna Media Contact:
SOURCE Kyverna Therapeutics | ||||||||||||||||||||||||||
View original content to download multimedia:
